POLYMER BULLETIN, cilt.80, sa.2, ss.2171-2185, 2023 (SCI-Expanded)
Research has commonly utilized graphene-based drug delivery systems for a long
time to achieve efective cancer treatment. In the present study, doxorubicin (DOX)
and selective estrogen receptor modulator tamoxifen (TAM) anticancer drugs used
in breast cancer treatment were bound to a graphene oxide (GO)-based and folic
acid (FA)-targeted nanocarrier system that was made biocompatible with chitosan
(CS). To this end, graphene oxide synthesis was primarily carried out by employing the modifed Hummer’s method, and then FA and CS were loaded on GO to
obtain a targeted and biocompatible carrier The characterization of the obtained
conjugate was performed by X-ray difraction analysis, Fourier transform infrared
spectroscopy, UV-visible spectrophotometry, scanning electron microscopy, and
zeta potential analysis. The zeta potential values of all samples were checked and
all of them have a zeta potential above the stability value of±25 mV. GO-CS-FA
has the highest zeta potential of 68.8 mV. The graphene oxide-chitosan-folic acidtamoxifen-doxorubicin (GO-CS-FA-TAM-DOX) nanocarrier-based drug displayed
a pH-dependent drug release. The drug release profle from these systems was
researched in two pH bufer solutions prepared as acidic (pH 5.8) and physiological
(pH 7.4). The characterization analyses showed that the drugs bound successfully to
the targeted delivery system. The drug release analyses demonstrated that GO-CSFA-TAM-DOX was released better in the acidic (pH 5.8) medium compared to the
physiological (pH 7.4) medium after 24 h.